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Heterogeneity of immune complex-derived anti-DNA antibodies associ-
ated with lupus nephritis. The mechanisms responsible for the tissue
injuries associated with lupus nephritis have not yet been well ex-
plained. We have investigated the characteristics of anti-DNA antibod-
ies in circulating immune complexes (CIC) and in the deposits of renal
glomeruli in patients with active lupus nephritis. The CIC-derived
antibodies expressed anti-DNA idiotypes (Id) designated as 0-81 Id and
NE-I Id, and bound mainly to single-stranded DNA but never to
glomerular basement membrane (GBM) antigens. On the other hand,
the immunoglobulins (Ig) eluted from renal glomeruli of lupus patients
reacted not only with DNA but also with GBM, proteoglycan, and
heparan sulfate. The binding of glomeruli-deposited Ig was markedly
low when GBM antigens were used after treatment with heparitinase,
suggesting that some anti-DNA antibodies may bind directly to GBM
antigens associated with heparan sulfate, and form in situ IC in renal
glomeruli. It was also revealed that the renal eluates obtained after
passing through GBM antigen-coupled Sepharose lost the binding
ability with GBM but still retained DNA-binding and 0-81 Id activity,
showing the participation of circulating IC-derived anti-DNA antibodies
in the glomerular deposits. Theoretically there may be two mechanisms
in the pathogenesis of lupus nephritis through the deposition of circu-
lating IC and through in situ formation of anti-DNA IC in renal
glomeruli. The diversity of histological features in lupus kidneys may be
attributed to the heterogeneity of the mechanisms.
Anti-DNA antibody activity is closely associated with the
disease activity of systemic lupus erythematosus (SLE) and the
autoantibodies have been assessed to play an important role in
the pathogenesis of the disease, especially in the renal lesions.
This was confirmed by evidence showing the deposition of
anti-DNA antibodies and their idiotypes (Id) in the renal gb-
meruli [1—31. Thus, SLE has been held to be typical of immune
complex diseases. Several mechanisms have been proposed to
account for the pathogenesis of the disease, One is the deposi-
tion of circulating anti-DNA immune complexes in the renal
glomeruli or in the skin, resulting in tissue injuries through
autoimmune or inflammatory processes. Definite evidence for
the role of circulating anti-DNA IC, however, has been sparse
[4, 51 because of the difficulty of exposing antigen-binding sites
in the IC-forming antibodies [6, 71. Another mechanism may be
in situ immune complex formation of anti-DNA antibodies in
the renal tissues. It has been suggested that the cationic
anti-DNA antibodies interact with negatively-charged glomeru-
bar basement membrane (GBM) antigens in the renal glomeruli
of lupus mice [8, 91. Human anti-DNA antibodies also have the
ability to bind with proteoglycan or heparan sulfate which are
normal constituents of GBM [101. Izui, Lambert and Miescher
also indicated that DNA could bind to positively charged GBM
components in mice and subsequently react with serum anti-
DNA antibodies [11]. These findings, however, have been
obtained from studies using monoclonal or serum anti-DNA
autoantibodies, of which the role in renal injuries in vivo has not
been evident, Thus, the exact mechanisms responsible for the
disease have not been thoroughly elucidated [12, 131.
We recently identified specific clonotypes expressing anti-
DNA Id (0-81 Id) in circulating IC of patients with active lupus
nephritis [14]. Since the immunoglobulins eluted from renal
gbomeruli of lupus patients also included 0-81-Id positive anti-
bodies, anti-DNA antibodies expressing 0-81-Id might be
nephritogenic. We demonstrate here the binding specificity of
the antibodies originating from circulating immune complexes
and from their renal eluates.
Methods
Samples
Plasma samples were obtained from 15 patients with active
lupus nephritis and from 25 controls including other renal
diseases. All SLE patients studied here fulfilled the 1982 criteria
of the American Rheumatism Association (ARA) for the diag-
nosis of SLE. Disease activity was defined by clinical signs and
symptoms (nephritis, arthritis, serositis, cerebral signs) accord-
ing to the criteria of Budman, Lizzio and Reeves [15]. All of the
patients with active lupus nephritis presented here showed
abnormal urinalysis, a reduced total hemolytic complement
level (CH50) and active nephropathy as determined by renal
biopsy [16, 17].
Monoclonal antibodies
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Human monoclonal anti-DNA antibodies (0-81 and NE-i)
were obtained from EBV-transformed B cell clones originated
from SLE with active lupus nephritis [18]. 0-81 Antibody binds
preferentially to single-stranded (ss)-homopolymer with pyrim-
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Table 1. Specificity of monoclonal antibodies
mAb Class Specificity
0-81 human 1gM ssDNA
NE-I human 1gM ss/dsDNA
7F4 human 1gM ss/dsDNA
D1E2 mouselgG1 idiotypes of 0-81
1F5 mouse IgG1 idiotypes of NE-I
idine bases and NE-i reacts not only with ssDNA but also with
double-stranded (ds)DNA, dsRNA, zDNA and cardiolipin [17,
19]. 7F4 was from human-human hybridoma originated from a
normal subject and reacted with ss/dsDNA, cardiolipin and
vimetin. Two types of monoclonal anti-idiotypic antibody
(DIE2 and 1F5) to human monoclonal anti-DNA antibodies
(0-81 and NE-I) were obtained from mouse hybridoma using
cells immunized with purified 0-81 or NE-i. D1E2 binds to
idiotypes (Id) which have the antigen-binding site of 0-81 and
inhibits the binding of 0-81 to ssDNA but does not react with
NE-i. 1F5 specifically blocks the interaction between NE-i and
dsDNA but never DNA-binding of 0-81 or 7F4 (Table 1) [20].
Reagents
Calf thymus DNA was obtained from Worthington Biochem-
icals. The DNA was further purified into double-stranded (ds)
and single-stranded (ss) DNA as described before [21]. Cardi-
olipin and histones were purchased from Sigma Chemical
Company (St. Louis, Missouri, USA) and haparan sulfate from
bovine kidney, hyaluronic acid from hog skin, chondroitin
sulfate from whale cartilage, chondroitin sulfate B from shark
cartilage, and chondroitin sulfate C from hog skin were ob-
tained from Seikagaku Koygo Ltd. (Tokyo, Japan). Hepariti-
nase from Favobacterium heparinum, trypsin and nuclease S
were also purchased from Seikagaku Kogyo, and DNAse I from
Sigma Laboratory.
Preparation of glomerular basement membrane (GBM)
antigens and proteoglycan
Glomeruli were isolated from fresh swine kidneys at 4°C by
the sieving method [221. The efficiency of the glomerular
isolation was monitored by checking the suspension under a
dissecting microscope. The glomeruii thus obtained were then
sonicated for six minutes at 200 W and centrifuged at 3000 rpm
in 1 M NaCl solution. After being dissolved in distilled water,
the pellets were washed five times with centrifugation at 3000
rpm for 10 minutes. The GBM fractions were dissolved with
0.15 M Tris-HC1 buffer, pH 2.3 at 1% final concentration,
digested with collagenase and then with deoxyribonuclease at
37°C for two hours. The obtained supernatant was concentrated
and dialyzed against distilled water for five days and finally
lyophyilized.
The GBM fraction was chromatographed in a DEAE-cellu-
lose column equilibrated with 50 m sodium phosphate (pH
7.0) containing 7 M urea. The column was washed with the same
buffer and linear gradient elution was carried out with NaCI in
the buffer. After pooled and submitted to a second DEAE-
cellulose chromatography, the major proteoglycan fraction was
further filtrated on a sepharose CL-6B column equilibrated and
eluted with 4 M guanidine HCI, 0.05 M sodium phosphate, pH
7.0. GBM was treated with heparitinase, at 37°C for 30 minutes,
dialyzed against 0.15 M PBS, pH 7.2 for overnight and then used
as antigens in some experiments.
Isolation of immune complexes from plasma
Circulating immune complexes (IC) were isolated from the
plasma sample using anti-C3 affinity columns. In order to
prepare the column, highly purified human C3 was first obtained
[23, 24] and immunized to rabbits. The immunized sera were
purified by affinity chromatography using human C3-Sepharose
CL-6B [25]. Then the obtained anti-C3-rabbit IgG was coupled
to Sepharose and used for the isolation of the circulating IC.
The plasma sample was first precipitated by 3.5% polyethylen-
glycol at final concentrations. The precipitates were dissolved
in PBS, pH 7.2 and passed through an affinity-purified anti-C3
IgG-coupled Sepharose. After washing with PBS, the immune
complexes bound to anti-C3 Sepharose were eluted with 0.15 M
glycine-HCI buffer, pH 2.3, neutralized with 3 M Tris-HCI, pH
10.0 and then stored at —70°C until use.
Elution of immuno globulins from kidneys
The renal tissues were obtained from three autopsy cases
with lupus nephritis (T.M, S.C, and N.T), from one case with
chronic glomerulonephritis (N.Y.), and from three control
subjects with esophageal cancer, gastric cancer or Behget's
disease, who had not manifested the glomerular injuries. The
renal histological findings in T.M, S.C, and N.T showed diffuse
proliferative glomerulonephritis classified as IV by WHO crite-
ria [7]. Each sample was minced into small pieces, suspended in
0.15 M PBS, pH 7.2, and then homogenized in a chilled Waring
Blender. Then the renal glomeruli were obtained by sieving
methods as described for the preparation of GBM antigen. The
obtained glomeruli were washed repeatedly with PBS by cen-
trifugation at 2000 x g until the optical density of the superna-
tant read less than 0.05 at 280 nm, then suspended in citrate
buffer, pH 3.2 and incubated at 37°C for one hour with contin-
uous shaking. After being centrifugated at 2000 x g 4°C for 15
minutes, the eluates were pooled and dialyzed against water for
two hours, then against 0.02 M PBS, pH 7.2 for 24 hours. The
eluates were concentrated approximately 25-fold with an Ami-
con filter and stored at —70°C until use.
Measurement of antibody activity
Each sample obtained from circulating IC, the glomerular
eluates or monoclonal antibody was fractionated in 4.5 M
urea-containing PBS (0.15 M) with gel tiltration using a Sepha-
cryl S-300 column, The resulting fractions were dialyzed against
0.15 frI PBS, pH 7.2 and then tested for the antibody activity.
Antibody activity was measured mainly with modified solid
phase radioimmunoassay [19]. SsDNA (2 g/ml), dsDNA (2
g/ml), GBM, proteoglycan, heparan sulphate, hyaluronic acid
or chondroitin sulphate A, B, C at 2.5 g/ml were incubated in
96-well polystyrene microplates (Coster 2985) precoated with
100 sl of protamine (1 mg/mI) overnight at room temperature.
Excess antigens were removed and 200 d of 3% fetal bovine
serum (FCS) were added to each well. After incubation for 60
minutes, followed by extensive washing with PBS containing
0.1% bovine serum albumin (BSA) and 0.05% Tween-20, seri-
ally diluted samples were allowed to react with antigen in the
wells for 90 minutes at 37°C. After the wells were washed with
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Fig. 1. Direct binding to GBM antigen. Each
sample was tested for the binding ability to
GBM antigen (-) or to heparitinase-treated
GBM antigens (. . .) as described at Methods.
A. Samples from human monoclonal
antibodies NE-i or 0-81. B. Samples from
Immunoglobulins isolated from circulating
immune complexes of SLE (•) or other
kidney diseases (0). C. Samples from
glomerular IgG of SLE case T.M (A), S.C (D)
and N.T (A) or of kidney disease case, N.Y
(a).
washing buffer, affinity-purified anti-human y F(ab')2 or anti-
human t F(ab')2 labeled with 1251 was added. The mixture was
incubated for two hours at room temperature, and the radioac-
tivity bound to each well was determined by a gamma counter.
Competitive inhibition RIA
A solid-phase competitive inhibition RIA was performed by
an inhibition to DNA-binding of anti-DNA antibodies. Prior to
inhibition, each sample was diluted to the middle point of the
maximum binding to DNA. A mixture of the test sample and 50
d of inhibitors at varying dilutions were incubated for 90
minutes in the well coated with ssDNA at 37°C. The results of
inhibition were expressed as percentage inhibition of anti-DNA
antibody-binding activity. Competitive inhibition assays were
also performed by a modified Farr assay. A 10 u1 sample of the
purified antibodies from immune complexes was mixed with 100
l.d (3 x iO cpm) of '251-labeled E. co/i plasmid DNA (1000 bp,
Nippon DPC Corporation, Chiba, Japan) and 10 pi of unlabeled
inhibitor at varying dilutions. After they had been incubated for
90 minutes at room temperature, an equal volume of saturated
ammonium sulphate was added to the mixtures. The immune
complexes were precipitated by centrifugation (2000 x g) at 4°C
for 15 minutes and the radioactivity was determined on a
gamma counter.
Absorption of antibody activity in the samples by a DNA or
an GBM antibody column
DNA or GBM antigens were coupled with CNBr-activated
Sepharose 4B as described before [26]. The samples were
passed through a DNA- or a GBM-coupled Sepharose 4B
column and then tested to determine anti-DNA antibody activ-
ity.
Results
Direct binding of the glomerular deposited and circulating
immune complex-derived antibodies
We isolated the immune complexes (IC) from plasma and the
eluates from the renal glonieruli. Each sample was further
fractionated as IgG or 1gM with gel filtration in 4.5 M urea-
containing PBS (0.15 M), and then tested for binding ability to
DNA or GBM antigens by using a solid phase RIA. The results
including human monoclonal anti-DNA antibodies (0-81, NE-i)
are shown in Figures 1 and 2. 1gM activity was found neither in
the preparations from circulating IC nor in those from the
glomcrular eluates (data not shown). All samples from SLE
bound to DNA. However, the reactivity to swine GBM which
showed cross-reactivity with human GBM [27] was variable.
The glomerular IgG from three cases with lupus nephritis
strongly reacted with GBM antigens as well as with DNA.
These samples also showed binding to proteoglycan, heparan
sulfate and chondroitin A. On the other hand, circulating
IC-derived antibodies from 15 SLE cases bound to DNA, but
failed to react with GBM-associated antigens. The binding of
the glomerular IgG from SLE was markedly low to hepariti-
nase-treated or to pepsin-treated GBM antigens (Fig. 1, Table
2). All samples of the renal eluates and of circulating IC from 20
control cases bound neither to DNA nor to GBM antigens.
Competitive inhibition RIA
These results prompted us to further study the binding
specificity of IC-derived antibodies by a competitive inhibition
RIA.
DNA-binding of circulating IC-derived antibodies from SLE
was blocked with the coexistence of free DNA but not with that
of GBM antigens. Similar results were obtained with 0-81 (data
not shown). On the other hand, the renal eluates decreased
DNA-binding ability when free DNA or GBM antigens were
added (Fig. 3). In some experiments, the inhibitor at the same
concentrations were first added for 90 minutes in wells coated
with ssDNA and washed. Then the test samples were again
tested for the inhibitory ability. The results were the same as
those in Figure 3 (data not shown).
We next sought to determine whether the glomerular eluates
still retained DNA-binding ability after an absorption of GBM
antigen-reactive antibodies. The glomerular eluates preab-
A B C
3
E
13)
00
13)
-c
-13C
.0
U5)
NE-i
3
2
2
3
2
0 10 io 10' io3 i0 10_i io
Concentration of 1g. g/m
Sasaki et a!: IC-derived anti-DNA antibodies 749
Direct binding capacity (x lO3cpm)
sorbed with an ssDNA or GBM-coupled column were tested for
binding ability to DNA. The ssDNA column completely ab-
sorbed both DNA- and GBM-binding ability in the eluates
(Table 3). The eluates after being preabsorbed with GBM also
failed to bind with GBM but to some extent, retained the
binding ability to ssDNA. DNA-binding capacity was inhibited
when GBM-absorbed samples were tested with the coexistence
of free ssDNA but not when tested with that of GBM antigens
(data not shown).
Then we tested for the expression of anti-DNA idiotypes (Id)
in IC-derived antibodies and in the glomerular eluates by a
competitive inhibition RIA using human monoclonal anti-DNA
antibodies (0-81, NE-i, and 7F4) or of murine monoclonal
anti-Id antibodies (D1E2 and iFS) as an inhibitor. As shown in
Figure 4, DNA binding of the samples from the glomerular
eluates of lupus patients and from circulating IC was strongly
inhibited by 0-81 and D1E2 (anti-Id to 0-81) and to a lesser
degree by NE-i and iFS (anti-Id to NE-i). The pooled 1gM, 7F4
and mouse IgG never blocked DNA-binding of the samples.
Discussion
This paper has described the properties of IC-derived anti-
DNA antibodies. The reasons why we studied IC-derived
antibodies in association with the pathogenesis of lupus nephri-
tis are as follows. Circulating anti-DNA antibodies expressing
0-8 1- or NE-i-Id occurred in 73% of SLE patients with active
lupus nephritis, but never in those lacking renal lesions [141.
Furthermore, 0-81 Id was proved to be deposited in lupus
kidneys (Suzuki, manuscript submitted for publication) and
0-81- or NE-i Id-positive anti-DNA antibodies could be eluted
from the necropsy cases with active lupus nephritis [141. These
Fig. 2. Direct binding to DNA or to GBM-
associated antigens. Twenty g/ml of Ig
purified from circulating IC or from
glomerular eluates were incubated with the
indicated antigens precoated in the wells.
Then the direct binding ability was determined
by a solid phase RIA. Symbols are: (•)
samples from circulating IC of active lupus
nephritis; (0) samples from circulating IC of
other diseases; (U) samples from glomerular
eluates of lupus nephritis; (0) samples from
glomerular eluates of other diseases.
data indicate that circulating IC-derived anti-DNA antibodies
expressing 0-81 Id may well be nephritogenic.
The samples from plasma or from the renal glomeruli might
still be in a immune complex form, where antigen-binding sites
of the antibodies were masked with IC-forming antigens, result-
ing in difficulty in analyzing the binding specificity of IC-derived
antibodies. In order to overcome this problem, we separated
the complex-derived antibodies from the bound antigens by
using 6 M urea, followed by the gel filtration. The possibility
remains that the renal eluates might include Ig originating in
blood or in urine contaminants arising in the preparation. This
is unlikely because we obtained renal glomeruli by a sieving
method. The samples were more than 95% renal glomeruli (data
not shown). Other evidence is that the Ig class of the renal
eluates was exclusively IgG, whereas plasma or urine in the
patients included both IgG and 1gM. In addition, the spectro-
typic profiles of Ig from the renal eluates were apparently
different from those in plasma or urine [14]. These data suggest
that the renal eluates presented here originated from IC in the
glomeruli.
We should also discuss DNA contamination in GBM or
proteoglycan antigens used in this experiments. Circulating
IC-derived anti-DNA antibodies reacted with DNA, but failed
to bind to GBM antigens, indicating that GBM or proteoglycan
antigens at the concentration presented here did not contain
immunologically active DNA. Another evidence is the failure of
detecting DNA in GBM or proteoglycan using electrophoresis
(data not shown), where 0.05 sg of DNA were detectable in the
presence of ethidium bromide [281. In addition, the glomerular
eluates from SLE cases reacted with DNAse- or nuclease S1
treated GBM as well as with the nontreated, but showed
markedly decreased binding to heparitinase-treated GBM. The
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Table 2. Effect of treatment with the enzymes on Ig-binding to GBM antigens
Duration
Treatment mm Gi-Ig (T.M.)
Binding to
GI-Ig (S.C.) Gi-Ig (H.K.) dC-NT (N.T.)
Fig. 3. Competitive inhibition RIA using
GBM-associated antigens. Twenty jsl/ml of
samples from circulating IC (IC-NS, IC-TM,
IC-TI-I, IC-SC, IC-MK, IC-NT) or from
glomerular eluates (Gl-SC, Gl-TM, G1-NT)
of SLE cases were incubated with a equal
volume of each antigen at the indicated
concentrations in wells precoated with ssDNA
and then assayed for anti-DNA activity. The
data were expressed as percent inhibition of
the uninhibited DNA binding (1,500 to 5,700
cpm). Symbols for inhibitors are: (0) ssDNA;
(®) dsDNA; (S) GBM antigens; (Li)
chondroitin A; (A) chondroitin B; (0)
chondroitin C ;(•) heparan sulphate.
above mentioned data indicate that glycosaminoglycan antigens
may be responsible for the reaction of the glomeruli-deposited
antibodies. Another problem is a possible involvement of
histones in the GBM preparation. Histones have a very high
affinity to the negatively charged GBM [29] and the possibility
remains that GBM included histones in the preparation or that
None — 4712 102 3954 241 102 11 123 13
Heparitinase 0.1 U/mI 30 1031 101 1599 114
0.5 U/mI 30 830 59 1054 93 102 10 119 23
Trypsin 5 g/ml 1 312 25 213 18
10 g/ml 1 202 34 159 17 107 9 115 16
DNAse 100 U/mI 30 4599 319 3990 295 Ill 14
Nuclease S1 100 U/mI 30 4752 146 3888 311 134 8
GBM antigen as treated with the indicated enzymes at 37°C for I or 30 mm. The direct binding assay to the treated GBM was carried out as
described in Methods, and total binding to the treated GBM-coated well minus the binding to BSA-coated well was described as the direct binding.
Each assay was done in triplicate. Data are mean SE.
Gi-Ig (T.M.) or Gl-lg (S.C) was glomerular Ig from SLE patient, TM. or S.C., and Gl-Ig (H.K.) from renal disease, ilK. CIC-NT was
circulating IC-derived Ig from SLE patient, NT.
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Table 3. Absorption tests of glomerular Ig by an affinity column
Glomerular
eluates from Absorbenta
Direct binding' to
ssDNA GBM D1E2
—
iFS mouse Ig
T.M.
T.M.
T.M.
T.M.
T.M.
T.M.
BSA
ssDNA
GBM
D1E2
1F5
mouse Ig
5115 112
311 19
2002 101
2514 112
4080 155
5508 259
4094 153
415 111
302 100
3517 299
2958 184
4155 153
3153 54
294 19
3095 199
199 12
2998 58
3004 156
2950 212
333 39
1219 256
2755 154
302 50
2859 130
211 35
192 19
232 18
186 19
180 9
271 20
C.S.
C.S.
C.S.
C.S.
CS.
C.S.
BSA
ssDNA
GBM
D!E2
IFS
mouse Ig
4008 251
294 18
2043 57
2158 154
3078 94
4199 158
2859 310
639 48
305 100
3055 195
2440 102
2958 113
3513 114
404 14
3430 195
293 8
3315 17
3499 28
1912 94
724 19
897 45
1738 53
40! 18
2000 12
118 19
209 13
192 8
200 11
198 11
113 18
N.Y.
N.Y.
N.Y.
N.Y.
BSA
ssDNA
GBM
D1E2
214 19
205 15
211 13
198 7
300 7
271 11
315 29
287 18
295 9
231 14
219 19
242 23
ND
ND
ND
ND
ND
ND
ND
ND
ND, not done
a Each sample was absorbed by an equal volume of the indicated antigen-coupled Sepharose and then tested for antigen-binding ability by
ELISAb
cpm
c T.M. and C.S. were patients with active lupus nephritis and N.Y. was patient with chronic glomerulonephritis
part of the isolated anti-DNA antibodies are still complexed to
nucleosomes [301. The glomerular eluates, however, did not
react with histones and we used IgG fraction obtained by
Sephacryl S 300 gel filtration, indicating that the prepared
glomerular IgG were not in a immune complex form.
Our data demonstrated that all samples from lupus glomeruli
preferentially bound to GBM and its associated antigens. This
findings is consistent with the previous observation that the
antibodies eluated from MRL/lpr/lpr mice kidney reacted with
heparan sulphate, the major glycosaminoglycan constituent of
GBM [311. This raises the possibility that anti-DNA antibodies
deposited in the renal glomeruli might have originated from free
anti-DNA antibodies in circulation, and that serum anti-DNA
antibodies bound directly to structures within renal glomerular
tissues which share the same epitopes recognized by the
antibodies [32]. This is supported by in vivo studies, where
exogeneously administered anti-DNA antibodies caused renal
dysfunction in mice [33] or in the rat whose kidney was
perfused [34]. Thus, certain antibodies which bind to GBM
antigens may preferentially form in situ immune complexes at
renal glomeruli in vivo.
Another important finding is that the glomerular eluates still
retained anti-DNA activity even after a complete absorption of
GBM-binding antibodies, indicating another mechanism for
immune deposits in the renal lesions. DNA has the ability to
bind to GBM in vitro through charge-charge interaction [11] and
to localize within the glomeruli in vivo [351, so that circulating
DNA could be planted in the glomeruli. Then the tissue-bound
antigens might react with free anti-DNA antibodies in the
circulation. Experiments suggesting this mechanism have re-
cently been employed in vivo [361. Our data may support this
mechanism. We, however, prefer to speculate that circulating
IC might be responsible for the immune deposition in renal
tissues, as demonstrated by Dixon, Feldman and Vazquez [371.
This mechanism has been challenged by data showing unsuc-
cessful trials for the presence of DNA antigens as well as
antibodies in circulating IC [6, 7, 12, 13]. In our experiments,
GBM-absorbed glomerular Ig reacted specifically with DNA
and expressed anti-DNA antibody-associated 0-81 Id and NE-I
Id. We previously demonstrated that some populations of
anti-DNA antibodies deposited in glomeruli were identical with
those of circulating IC-forming anti-DNA antibodies expressing
0-81 or NE-I Id when analyzed by an isoelectrofocusing study
[14]. These data suggest that some types of antibodies deposited
in renal glomeruli may originate from circulating IC. Thus, our
data suggest that there might be at least two mechanisms for the
immune deposits in renal glomeruli of lupus patients. One is
associated with tissue deposition from circulating anti-DNA IC
and the other with in situ IC formation at renal glomeruli by
serum anti-DNA antibodies, which have a cationic charge [141.
It is very interesting to speculate that our data might be
associated with histological or immunological features in renal
glomeruli. Experimentally, the circulating IC brought about
deposition on the mesangeal and the endothelial areas, whereas
the subepithelial deposits, which can be observed in idiopathic
membranoglomerulonephritis in humans, may arise by in situ
IC formation associated with cationic charged antigens or
antibodies [38, 391. in lupus nephritis, immune deposits in
subepithelial areas are often accompanied with mesangeal and
subendothelial immune deposits, and their histological changes
are diverse [16, 17], indicating that the complexity of renal
lesions in SLE may be attributed to the heterogeneity of the
mechanisms presented here. Thus, analysis of circulating
nephritogenic antibodies in association with histological
changes will provide us with important information concerning
their clinical significance as well as their role in the pathogen-
esis of lupus nephritis.
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